CD200 receptor program (Schering-Plough Biopharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD200 receptor program (Schering-Plough Biopharma)

Drug Alias Nameanti-CD200 monoclonal antibody (DNAX)CD200 receptor program (DNAX)CD200-IgG fusion proteinOX2 receptor agonists (Schering-Plough Biopharma)CD200-IgG fusion protein (Schering-Plough Biopharma) +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionOrexin receptor type 2 agonists

TargetsOrexin receptor type 2

Therapy Area/IndicationsArthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSchering-Plough Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSchering-Plough Corp

Active IndicationsN/A

Inactive IndicationsArthritis

Other Information

ATC CodeN/A